NDAINTRAVENOUSSOLUTION
Approved
Oct 2022
Lifecycle
Peak
Competitive Pressure
0/100
Data completeness
3/8 — Basic
NOREPINEPHRINE BITARTRATE IN 0.9% SODIUM CHLORIDE (norepinephrine bitartrate) by Infinant Health is (alpha-adrenergic action) and an inotropic stimulator of the heart and dilator of coronary arteries (beta-adrenergic action). First approved in 2022.
Drug data last refreshed 18h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
Norepinephrine bitartrate in 0.9% sodium chloride is an intravenous catecholamine used to restore and maintain blood pressure in acute hypotensive states. It works via dual alpha-adrenergic vasoconstriction and beta-adrenergic inotropic and coronary vasodilatory actions. This formulation (NDA approved October 2022) represents a standardized IV solution for critical care settings.
Peak11.7 years to LOE
Recent peak-stage approval with no generic competition and strong patent protection suggests stable commercial team with focus on hospital formulary management and critical care penetration.
Mechanism of Action
(alpha-adrenergic action) and an inotropic stimulator of the heart and dilator of coronary arteries (beta-adrenergic action).
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Working on this product offers stability in a non-growth but defensible market segment with clear IP protection through 2038. Roles emphasize hospital relationships, formulary negotiations, and critical care penetration rather than patient-facing or launch strategy work.
Hospital Account ManagerSupply Chain / Logistics Manager
Worked on NOREPINEPHRINE BITARTRATE IN 0.9% SODIUM CHLORIDE at Infinant Health? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.